Molecular nanomedicine towards cancer: 111In-labeled nanoparticles

Journal of Pharmaceutical Sciences

Volumn 101, Issue 7, 2012, Pages 2271-2280

  Psimadas, Dimitrios ^a,b   Georgoulias, Panagiotis ^a   Valotassiou, Varvara ^a   Loudos, George ^b  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

Distribution; Imaging methods; Liposomes; Micelles; Nanoparticles

Indexed keywords

GELATIN; GOLD NANOPARTICLE; INDIUM 111; IRON OXIDE; LIPOSOME; MACROGOL; NANOCARRIER; NANOPARTICLE; PENTETIC ACID; SINGLE WALLED NANOTUBE; TECHNETIUM 99M; TETRAXETAN; DIAGNOSTIC AGENT; INDIUM; RADIOPHARMACEUTICAL AGENT;

CANCER DIAGNOSIS; GEL PERMEATION CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; MICELLE; MOLECULAR INTERACTION; NANOTECHNOLOGY; NEOPLASM; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RETICULOENDOTHELIAL SYSTEM; REVIEW; ROOM TEMPERATURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THIN LAYER CHROMATOGRAPHY; ANIMAL; CHEMISTRY; HUMAN; METHODOLOGY; NANOMEDICINE; SCINTISCANNING;

ANIMALS; HUMANS; INDIUM; MICELLES; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84866268384     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23146     Document Type: Review

References (65)

1. Reubi JC, Maecke HR. 2008. Peptide-based probes for cancer imaging. J Nucl Med 49:1735-1738.
2. Imam SK. 2005. Molecular nuclear imaging: The radiopharmaceuticals. Cancer Biother Radiopharm 20:163-172.
3. Hawkins RA. 2000. Radionuclide imaging in cancer medicine. In Holland-Frei Cancer Medicine; Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, Eds. 5th ed. Hamilton, Ontario: BC Decker Inc: Chapter 30H.
4. Massoud TF, Gambhir SS. 2002. Molecular imaging in living subjects: Seeing fundamental biological processes in a new light. Genes Dev 17:545-580.
5. Berman DS, Kiat H, van Train K, Friedman JD, Wang FP, Germano G. 1994. Dual-isotope myocardial perfusion SPECT with rest thallium-201 and stress Tc-99m sestamibi. Cardiol Clin 12:261-270.
6. Cutler CS, Lewis JC, Anderson CJ. 1999. Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis. Adv Drug Deliv Rev 37:189-211.
7. Anderson CJ, Welch MJ. 1999. Radiometal-labeled agents (non-technetium) for diagnostic imaging. Chem Rev 99:2219-2234.
8. Jurisson S, Cutler C, Smith CV. 2008. Radiometal complexes: Characterization and relevant in vitro studies. Q J Nucl Med 52:222-234.
9. Wang MD, Shin DM, Simons JW, Nie S. 2007. Nanotechnology for targeted cancer therapy. Exp Rev Anticancer Ther 7:833-837.
10. Hoet PH, Brüske-Hohlfeld I, Salata OV. 2004. Nanoparticles-Known and unknown health risks. J Nanobiotechnology 2(1):12.
11. Choi HS, Frangioni JV. 2010. Nanoparticles for biomedical imaging: Fundamentals of clinical translation. Mol Imaging 9:291-310.
12. Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, Langer RS, Farokhzad RS. 2007. Targeted nanoparticles for cancer therapy. NanoToday 2:14-21.
13. Lian T, Ho RJ. 2001. Trends and developments in liposome drug delivery systems. J Pharm Sci 90:667-80.
14. Kumar CS, Mohammad F. 2011. Magnetic nanomaterials for hyperthermia-based therapy and controlled drug delivery. Adv Drug Deliv Rev 63:789-808.
15. Schladt TD, Schneider K, Schild H, Tremel W. 2011. Synthesis and bio-functionalization of magnetic nanoparticles for medical diagnosis and treatment. Dalton Trans 40:6315-6343.
16. Torchilin VP. 2006. Multifunctional nanocarriers. Adv Drug Deliv Rev 58:1532-1555.
17. Maeda H, Matsumura Y. 1989. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6:193-210.
18. Gil PR, Parak WJ. 2008. Composite nanoparticles take aim at cancer. ACS Nano 2:2200-2205.
19. Boerman OC, Laverman P, Oyen WJG, Corstens FHM, Storm G. 2000. Radiolabeled liposomes for scintigraphic imaging. Progr Lipid Res 39:461-475.
20. Gref R, Minamitake Y, Peracchia V, Trubetskoy V, Torchillin V, Langer R. 1994. Biodegradable long-circulating polymeric microspheres. Science 263:1600-1603.
21. Blume G, Cevc G, Crommelin MD, Bakker-Woudenberg IA, Kluft C, Storm G. 1993. Specific targeting with poly(ethylene glycol)-modified liposomes: Coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochim Biophys Acta 1149:180-184.
22. Immordino ML, Dosio F, Cattel L. 2006. Stealth liposomes: Review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 1:297-315.
23. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. 2007. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release 120:18-26.
24. Liu Y, Miyoshi H, Nakamura M. 2007. Nanomedicine for drug delivery and imaging: A promising avenue for cancer therapy and diagnosis using targeted functional nanoparticles. Int J Cancer 120:2527-2537.
25. Lee HY, Li Z, Chen K, Hsu AR, Xu C, Xie J, Sun S, Chen X. 2008. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 49:1371-1379.
26. McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, Brentjens R, Scheinberg DA. 2007. Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 48:1180-1189.
27. Saad M, Garbuzenko OB, Ber E, Chandna P, Khandare JJ, Pozharov VP, Minko T. 2008. Receptor targeted polymers, dendrimers, liposomes: Which nanocarrier is the most efficient for tumor-specific treatment and imaging? J Control Release 130:107-114.
28. Shokeen M, Fettig NM, Rossin R. 2008. Synthesis, in vitro and in vivo evaluation of radiolabeled nanoparticles. Q J Nucl Med Mol Imaging 52:267-277.
29. Lucignani G. 2009. Nanoparticles for concurrent multimodality imaging and therapy: The dawn of new theragnostic synergies. Eur J Nucl Med Mol Imaging 36:869-874.
30. Elbayoumi TA, Pabba S, Roby A, Torchilin VP. 2007. Antinucleosome antibody-modified liposomes and lipidcore micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res 17:1-14.
31. Ting G, Chang CH, Wang HE, Lee TW. 2010. Nanotargeted radionuclides for cancer nuclear imaging and internal radiotherapy. J Biomed Biotechnol 2010:953537.
32. 99mTc-labeled liposome encapsulated cyclosporine. J Drug Target 11:187-196.
33. Laverman P, Boerman OC, Oyen WJ, Dams ET, Storm G, Corstens FH. 1999. Liposomes for scintigraphic detection of infection and inflammation. Adv Drug Deliv Rev 37:225-235.
34. Elbayoumi TA, Torchilin VP. 2006. Enhanced accumulation of long-circulating liposomes modified with thenucleosome-specific monoclonal antibody 2C5 in various tumours in mice: Gamma-imaging studies. Eur J Nucl Med Mol Imaging 33:1196-205.
35. Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ. 2004. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys 58:1215-1227.
36. Torchilin VP, Lukyanov AN. 2003. Peptide and protein drug delivery to and into tumors: Callenges and solutions. Drug Discov Today 8:259-266.
37. Helbok A, Decristoforo C, Dobrozemsky G, Rangger C, Diederen E, Stark B, Prassl R, von Guggenberg E. 2010. Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: A comparison using different radiometals. J Liposome Res 20:219-227.
38. Hwang do W, Ko HY, Lee JH, Kang H, Ryu SH, Song IC, Lee DS, Kim S. 2010. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer. J Nucl Med 51:98-105.
39. Chakraborty S, Das T, Sarma HD, Venkatesh M, Banerjee S. 2008. Preparation and preliminary studies on 177Lu-labeled hydroxyapatite particles for possible use in the therapy of liver cancer. Nucl Med Biol 35:589-97.
40. Hamoudeh M, Kamleh MA, Diab R, Fessi H. 2008. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 60:1329-1346.
41. McCarthy JR, Weissleder R. 2008. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 60:1241-1251.
42. Hong H, Zhang Y, Sun J, Cai W. 2009. Molecular imaging and therapy of cancer with radiolabeled nanoparticles. Nano Today 4:399-413.
43. 99mTc labeled hybrid nanoparticle bearing a cobalt ferrite core: in vivo biodistribution. J Biomed Nanotechnol (in press).
44. Loudos G, Kagadis GC, Psimadas D. 2011. Current status and future perspectives of in vivo small animal imaging using radiolabeled nanoparticles. Eur J Radiol 78:287-295.
45. 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol 35:623-634.
46. 111in-VNB-liposome on human colorectal adenocarcinoma HT-29/luc mouse xenografts. Nucl Instr Methods Phys Res 569:497-504.
47. Zhang R, Xiong C, Huang M, Zhou M, Huang Q, Wen X, Liang D, Li C. 2011. Peptide-conjugated polymeric micellar nanoparticles for Dual SPECT and optical imaging of EphB4 receptors in prostate cancer xenografts. Biomaterials 32:5872-5879.
48. Zhang R, Lu W, Wen X, Huang M, Zhou M, Liang D, Li C. 2011. Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis. J Nucl Med 52:958-964.
49. Lee H, Hoang B, Fonge H, Reilly RM, Allen C. 2010. in vivo distribution of polymeric nanoparticles at the whole-body, tumor, and cellular levels. Pharm Res 27:2343-2355.
50. Lee H, Fonge H, Hoang B, Reilly RM, Allen C. 2010. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm 7:1195-1208.
51. Kommareddy S, Amiji M. 2007. Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J Pharm Sci 96:397-407.
52. 111In-ChL6 nanoparticle AMF-induced thermoablative therapy for human breast cancer in mice. J Nucl Med 48:437-444.
53. Melancon MP, Lu W, Yang Z, Zhang R, Cheng Z, Elliot AM, Stafford J, Olson T, Zhang JZ, Li C. 2008. in vitro and in vivo targeting of hollow gold nanoshells directed at epidermal growth factor receptor for photothermal ablation therapy. Mol Cancer Ther 7:1730-1739.
54. Singh R, Pantarotto D, Lacerda L, Pastorin G, Klumpp C, Prato M, Bianco A, Kostarelos K. 2006. Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc Natl Acad Sci U S A 103:3357-3362.
55. 111In nanoparticles. Int J Cancer 120:1951-1957.
56. 111In. J Nucl Med 50:582-590.
57. Pereira MA, Mosqueira VC, Carmo VA, Ferrari CS, Reis EC, Ramaldes GA, Cardoso VN. 2009. Biodistribution study and identification of inflammatory sites using nanocapsules labeled with (99m)Tc-HMPAO. Nucl Med Commun 9:749-755.
58. Kocher DC. 1981. Radioactive Decay Data Tables-A Handbook of Decay Data for Application to Radiation Dosimetry and Radiological Assessments, DOE/TIC-11026; U.S. Department of Energy, Oak Ridge, Tennessee: 115.
59. Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, Patri P, Pangerl T, Angelberger P, Raderer M, Burggasser G, Andreae F, Kurtaran A, Dudczak R. 2002. Experience with indium-111 and yttrium-90-labeled somatostatin analogs. Curr Pharm Des 8:1781-1807.
60. Meares CF, Moi MK, Diril H, Kukis DL, McCall MJ, Deshpande SV, DeNardo SJ, Snook D, Epenetos AA. 1990. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl 10:21-26.
61. Lasic DD, Papahadjopoulos D. 1995. Liposomes revisited. Science 267:1275-1276.
62. McAfee JG, Thakur ML. 1976. Survey of radioactive agents for in vitro labeling of phagocytic leukocytes. I. Soluble agents. J Nucl Med 17:480-487.
63. Rolland A, Collet B, Le Verge R, Toujas L. 1989. Blood clearance and organ distribution of intravenously administered polymethacrylic nanoparticles in mice. J Pharm Sci 78:481-484.
64. Torchilin VP. 2000. Polymeric contrast agents for medical imaging. Curr Pharm Biotechnol 1:183-215.
65. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. 2008. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm 5:505-515.